Minoxidil

證據等級: L5

預測適應症: 10 個

MINOXIDIL: From Androgenetic Alopecia to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Minoxidil is a potassium channel opener with established use in androgenetic alopecia, acting by promoting perifollicular vasodilation and extending the hair follicle anagen phase. The TxGNN model predicts it may be effective for Hypotrichosis Simplex of the Scalp — a rare hereditary hair follicle density disorder — with a near-perfect prediction score of 99.99992%. Current human evidence is limited to 0 clinical trials and 3 case reports/series, placing this candidate at Evidence Level L4.

Quick Overview

Item	Content
Original Indication	Androgenetic alopecia (international established use; no Canadian DINs on record)
Predicted New Indication	Hypotrichosis Simplex of the Scalp
TxGNN Prediction Score	99.99992%
Evidence Level	L4
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on known pharmacology, minoxidil acts as an ATP-sensitive potassium channel (K_ATP) opener. Activation of these channels in perifollicular vascular smooth muscle induces vasodilation, increasing blood flow to hair follicles. This upregulates vascular endothelial growth factor (VEGF) expression, prolongs the anagen (active growth) phase, and reduces the proportion of follicles in telogen (resting) phase. Minoxidil also exerts mild anti-androgenic and Wnt/β-catenin pathway modulatory effects, further supporting follicular activity.

Hypotrichosis Simplex of the Scalp (HSS) is a rare autosomal dominant condition caused by loss-of-function variants in the CDSN gene, which encodes corneodesmosin — a desmosomal protein critical for maintaining the structural integrity of hair follicles. The disease manifests as progressive reduction in scalp hair density, beginning in childhood, due to shortened anagen phases and follicular miniaturization. Because the underlying defect is functional rather than completely ablative (follicles are present but underperforming), minoxidil’s anagen-prolonging mechanism maps directly onto the disease pathophysiology.

This mechanistic alignment is strengthened by clinical extrapolation: the same mechanism has been validated in multiple RCTs for androgenetic alopecia, another non-scarring alopecia driven by follicular miniaturization and anagen shortening. The TxGNN model’s extremely high prediction score reflects this genuine biological overlap. However, HSS is a rare genetic disease with a distinct molecular etiology, and minoxidil cannot correct the CDSN gene defect — making it a symptomatic rather than disease-modifying intervention.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35761391	2022	Case Series	Dermatologic Therapy	Oral minoxidil combined with growth factors in hereditary HSS; demonstrates clinical feasibility of minoxidil as a therapeutic option for this orphan condition
36651821	2023	Case Report	Journal of Dermatological Treatment	14-year-old HSS patient treated with combined platelet-rich plasma injections and topical minoxidil 2%; reports improvement in hair density and length
39902296	2024	Case Report	Frontiers in Genetics	Familial HSS in an 8-year-old male with confirmed CDSN mutation, treated with botanical extracts plus minoxidil; documents symptomatic hair improvement and supports minoxidil’s role in genetically confirmed HSS

Canada Market Information

Minoxidil has no registered Drug Identification Numbers (DINs) in the Canadian regulatory database queried. The drug is recorded as not marketed in Canada per this dataset. Note: this may reflect a data gap, as minoxidil products are widely available internationally; verification against the Health Canada Drug Product Database directly is recommended.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence supporting minoxidil for hypotrichosis simplex of the scalp is limited to 3 small case reports/series with no controlled trials, and the rare genetic nature of HSS makes large-scale evidence generation challenging. Although the mechanistic rationale is strong and biologically plausible, the absence of safety data in the evidence pack and the lack of any controlled clinical evidence prevent a recommendation to proceed at this stage.

To proceed, the following is needed:

Retrieve complete safety data (key warnings, contraindications, drug interactions) from Health Canada product monograph or international package inserts for both topical and oral minoxidil formulations
Verify Canada market status directly against the Health Canada Drug Product Database to resolve the data gap
Obtain mechanism of action documentation from DrugBank (DB00350) to support regulatory submissions
Design a prospective case series or pilot study (n ≥ 10 HSS patients) with standardized endpoints (e.g., hair density by phototrichogram, anagen:telogen ratio by trichoscopy)
Evaluate orphan drug designation eligibility given the rarity of HSS
Assess cardiac and hemodynamic monitoring requirements, particularly for oral minoxidil use in pediatric populations where HSS commonly presents
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.